AU2012219288A1 - Methods for treating diseases of the retina - Google Patents

Methods for treating diseases of the retina Download PDF

Info

Publication number
AU2012219288A1
AU2012219288A1 AU2012219288A AU2012219288A AU2012219288A1 AU 2012219288 A1 AU2012219288 A1 AU 2012219288A1 AU 2012219288 A AU2012219288 A AU 2012219288A AU 2012219288 A AU2012219288 A AU 2012219288A AU 2012219288 A1 AU2012219288 A1 AU 2012219288A1
Authority
AU
Australia
Prior art keywords
group
het
alkyl
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012219288A
Other languages
English (en)
Inventor
Eric Beausoleil
Anne-Sophie Casagrande
Laurent J. R. Desire
John E. Donello
Bertrand Leblond
Matthew P. Pando
Veena Viswanath
Rong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exonhit SA
Allergan Inc
Original Assignee
Exonhit SA
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonhit SA, Allergan Inc filed Critical Exonhit SA
Publication of AU2012219288A1 publication Critical patent/AU2012219288A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012219288A 2011-02-18 2012-02-17 Methods for treating diseases of the retina Abandoned AU2012219288A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161444587P 2011-02-18 2011-02-18
US201161444602P 2011-02-18 2011-02-18
US61/444,602 2011-02-18
US61/444,587 2011-02-18
US201161482097P 2011-05-03 2011-05-03
US201161482106P 2011-05-03 2011-05-03
US61/482,106 2011-05-03
US61/482,097 2011-05-03
PCT/US2012/025685 WO2012112918A1 (en) 2011-02-18 2012-02-17 Methods for treating diseases of the retina

Publications (1)

Publication Number Publication Date
AU2012219288A1 true AU2012219288A1 (en) 2013-09-05

Family

ID=45787351

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012219288A Abandoned AU2012219288A1 (en) 2011-02-18 2012-02-17 Methods for treating diseases of the retina

Country Status (7)

Country Link
US (1) US20120214842A1 (enExample)
EP (1) EP2675456A1 (enExample)
JP (1) JP6038051B2 (enExample)
AR (1) AR085285A1 (enExample)
AU (1) AU2012219288A1 (enExample)
CA (1) CA2827509A1 (enExample)
WO (1) WO2012112918A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
FR3008618A1 (fr) * 2013-07-19 2015-01-23 Univ Paris Curie Utilisation de composes pour restaurer la reponse a la lumiere des cellules de la retine
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006072828A2 (en) * 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
AU2006311786A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis
JP2009535394A (ja) * 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物
KR100816670B1 (ko) * 2006-08-18 2008-03-27 국방과학연구소 망막 손상 치료 및 망막 보호하기 위한 메틸렌블루의 용도
CN101611029B (zh) * 2006-12-21 2014-09-10 辉瑞产品公司 2-((4-(1-甲基-4-(吡啶-4-基)-1h-吡唑-3-基)苯氧基)甲基)喹啉的琥珀酸盐
WO2011053559A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Aryl aminopyridine pde10 inhibitors

Also Published As

Publication number Publication date
US20120214842A1 (en) 2012-08-23
AR085285A1 (es) 2013-09-18
CA2827509A1 (en) 2012-08-23
WO2012112918A1 (en) 2012-08-23
JP6038051B2 (ja) 2016-12-07
JP2014506582A (ja) 2014-03-17
EP2675456A1 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
US20120214842A1 (en) Methods for treating diseases of the retina
AU2017272151B2 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
CA3179702A1 (en) Heteroaromatic macrocyclic ether chemotherapeutic agents
EP2146718A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CN103052406A (zh) 双官能rho激酶抑制剂化合物、组合物及应用
CN103249305A (zh) 使用前药形式的激酶抑制剂化合物治疗眼科疾病的方法
CN101005842A (zh) 蕈毒碱性受体调节剂
JP2019521189A (ja) ドライアイ、眼痛および炎症の処置のためのｔｒｐａ１アンタゴニスト
EP4183415A1 (en) Trpv4 inhibitor as therapeutic drug for eye disease
EP2716302B1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
WO2013077579A1 (ko) 안과 질환의 예방 및 치료용 약학 조성물
EP2611415A1 (en) Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
TW201927298A (zh) 賽佩普斯特（Ｓｅｐｅｔａｐｒｏｓｔ）及Ｒｈｏ激酶抑制劑之組合醫藥
WO2019124489A1 (ja) セペタプロストとｅｐ２アゴニストとの組み合わせ医薬
CN110650740A (zh) 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物
JP2022550539A (ja) Ｃｄｋ５の置換１，６－ナフチリジン阻害剤
KR101891846B1 (ko) (3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐)메탄올을 포함하는 약제학적 조성물
TW201335149A (zh) 治療視網膜疾病之方法
JPH11512444A (ja) 新規置換アザ環式またはアザ二環式化合物
WO2024017315A1 (zh) 甾体化合物在制备预防和/或治疗眼科疾病药物中的应用
JP2024514363A (ja) 修飾フェロポーチン阻害剤
WO2017035528A1 (en) Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
JP2016502498A (ja) 眼障害を治療する方法
TWI917308B (zh) 歐米德尼培（Ｏｍｉｄｅｎｅｐａｇ）之組合
JP3958391B2 (ja) 眼疾患用薬剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted